Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for us at medac. We have been active in this field from almost the very beginning of our company in the 1970s. As an internationally growing pharmaceutical company dedicated to improving human health, particularly in areas of high therapeutic needs, we are focused on developing a range of proprietary products that address a variety of unmet therapeutic needs.
Addressing unmet needs with urological therapies

Focussing on bladder cancer

Our work in urology is a well-proven example of how we successfully pursue our mission. The therapeutic niche we focus on is non-muscle invasive bladder cancer (NMIBC), specifically the adjuvant treatment in the first-line setting. As early as the end of the 19th century, doctors had made the observation that the tumours of some cancer patients shrank when they suffered from a high fever caused by a bacterial infection. This paved the way for the immunotherapy of cancer, where treatments specifically stimulate the body's own immune system and help it fight against the tumour – ultimately reducing the burden from the tumour.

The birth of immunotherapy

The tuberculosis vaccine Bacille Calmette-Guérin (BCG), introduced in the 1920s, contains attenuated pathogens of bovine tuberculosis. In studies in the 1970s, BCG was shown to be effective against bladder cancer as well, one of the most common tumour diseases in Europe. BCG triggers an immune reaction that is not specifically directed against the tumour but activates the body's immune system to eliminate the cancer cells.

Instillation therapy with medac

Instillation therapies in non-muscle invasive bladder cancer (NMIBC) have a long tradition at medac. With two well-established medications, we provide a dual first-line treatment concept for the adjuvant treatment of NMIBC. Powered by the needs of the users and to increase their personal safety, our experts developed the first closed instillation system on the market in 1988.

Today our system comes as standard with our compounds and it is highly regarded for its ease of use and safety by healthcare professionals from all over the world. 

Providing reliability in an undersupplied market

By continually developing our expertise over many years, we have been able to reliably serve the undersupplied NMIBC market with preparations for all risk classes, making our products available to patients in need.

Information for patients

Educational Material

In addition to the respective summary of product characteristics and the package leaflet, educational material approved by the national authorities is also available for some medac products. The educational material published below is the educational material approved in the respective EU Member State.

Our Focus Areas


Key rheumatological treatment improved

Rheumatic diseases imply a range of chronic treatment needs across a broad spectrum of patients. With the optimisation of a key treatment in this area, medac has succeeded in bringing a significant improvement to patients' quality of life.


Innovative and life-saving treatment options

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative products for therapies before and after stem cell transplantation.


Quality and innovation in supporting cancer care

Oncology has been a key focus and cornerstone of medac's success story throughout our corporate history. We have a strong, decades-long track record of reliable supply of medicinal products and supportive therapeutics across a range of oncological indications.